ClinicalTrials.gg
Not yet recruitingNCT07170384Updated Sep 12, 2025

Mediterranean Diet and Disease Activity in Axial Spondyloarthritis Receiving Biologic Therapy

An interventional study of Mediterranean Diet and Healthy Eating Advice in Axial Spondyloarthritis (Ankylosing Spondylitis), sponsored by Sinem Kübra Beke. Not yet recruiting at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-12.

Primary conditionSpondylitis, AnkylosingRegistry: Axial SpondyloarthritisReclassifiedWhy we changed it
Registry
Axial Spondyloarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spondylitis, Ankylosing
Why
  1. The study's listed conditions name Spondylitis, Ankylosing, a narrower term within Axial Spondyloarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sinem Kübra Beke · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Spondylitis, Ankylosing with a site in Turkey — 19 open to participants now, 21 under way, none of them phase 3. Spondylitis, Ankylosing · Turkey.

Planned enrollment
15th of 49
110 · median 60
Started
2025
with 8 others
No phase
37 of 84
12 open now
Primary completion
2027-01
later than 13 of 20 live
Registered
67th of 84
by date

Among the 84 studies in Spondylitis, Ankylosing with a site in Turkey, this one is the 15th largest by planned enrollment of the 49 interventional ones that give a count, is one of 9 that started in 2025, is one of 37 with no phase, reaches primary completion later than 13 of the 20 other live ones, and was the 67th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 84 studies in Spondylitis, Ankylosing with a site in Turkey are open now. Recruiting first, the newest first:

13 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Spondylitis, Ankylosing with a site in Turkey, or all of them as a file.
02

Study summary

This study aims to evaluate the effect of the Mediterranean diet on disease activity, quality of life, inflammation, pain, and treatment response in patients with axial spondyloarthritis (ankylosing spondylitis) who are receiving stable biologic therapy. Axial spondyloarthritis is a chronic inflammatory disease that affects the spine and sacroiliac joints, often leading to pain, stiffness, and reduced quality of life. While biologic disease-modifying antirheumatic drugs (bDMARDs) are effective in reducing inflammation, lifestyle factors such as diet may also play an important role in disease outcomes.

In this randomized controlled trial, a total of 110 patients diagnosed with ankylosing spondylitis will be enrolled. Participants will be randomly assigned to either the Mediterranean diet group or the control group. The Mediterranean diet group will receive a structured diet program supervised by a dietitian, while the control group will continue their standard care with general healthy eating advice. Patients will be monitored for dietary adherence, and assessments will be conducted at baseline and after 3 months.

The primary outcome measure is the change in Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP). Secondary outcomes include BASDAI, BASFI, BASMI, laboratory markers of inflammation, quality of life (SF-36), fatigue (FACIT-Fatigue), sleep quality (PSQI), anxiety and depression (HADS), medication adherence (MMAS-8), and Mediterranean diet adherence (PREDIMED). The study will provide valuable data on whether a Mediterranean diet can improve clinical outcomes and support the management of axial spondyloarthritis in patients receiving biologic therapy, potentially contributing to future lifestyle-based treatment strategies.

Read the detailed description

Aim This study is designed to investigate the effects of the Mediterranean diet on disease activity, quality of life, inflammation levels, pain scores, and the frequency of biologic DMARD use in patients with ankylosing spondylitis (AS) receiving biologic disease-modifying antirheumatic drugs (bDMARDs).

Background Ankylosing spondylitis (AS) is a chronic inflammatory disease that causes early inflammation in the sacroiliac joints and, in later stages, also affects the axial skeleton. Structural and functional impairment, together with inflammatory back pain, lead to a marked reduction in quality of life. Genetic factors, intestinal microbiota, mechanical stress on the spine and peripheral joints, innate immunity, oxidative stress, lifestyle, and environmental influences are thought to play important roles in the pathogenesis of AS.

Both pharmacological and non-pharmacological strategies are used in the treatment of AS. The primary goal of treatment is to control symptoms and inflammation, prevent structural damage, and maximize long-term quality of life. However, there is limited evidence supporting the effectiveness of lifestyle modifications. Among environmental factors, diet is a modifiable component with the potential to reduce inflammation. Certain foods may trigger inflammatory processes, whereas nutrients such as antioxidants and omega-3 fatty acids may exert anti-inflammatory effects.

The Mediterranean diet (MD), with its anti-inflammatory and antioxidant potential, is considered a promising dietary model in chronic inflammatory conditions. This dietary pattern emphasizes high consumption of olive oil, unrefined carbohydrates, fresh and dried fruits, vegetables, and fish; low consumption of dairy products and red meat; and moderate consumption of red wine. In AS, such nutrients may reduce inflammation, alleviate pain, decrease structural damage, and potentially improve quality of life. No study has specifically compared the Mediterranean diet in AS patients receiving stable bDMARD therapy with a control group. This trial is intended to address this gap.

Hypothesis The investigators hypothesize that the Mediterranean diet will reduce disease activity, improve quality of life, and lower inflammation in patients with AS.

Study Design and Participants This study is designed as a prospective, single-blind, randomized controlled trial. The required sample size was calculated as 51 patients per group. Considering a 10% dropout rate, 55 patients will be included in each group, resulting in a total of 110 participants. Patients older than 18 years who meet the Assessment of SpondyloArthritis International Society (ASAS) classification criteria for AS will be eligible after providing written informed consent.

Inclusion Criteria

Diagnosis of AS according to ASAS criteria

Age ≥18 years

No dietary changes in the last 3 months

Stable treatment (NSAIDs or DMARDs) for the previous 4 months

Willingness to participate

Exclusion Criteria

Pregnancy or breastfeeding

Nutritional restrictions preventing adherence to the Mediterranean diet

Participation in another diet- or exercise-based intervention program within the last 6 months

History of other rheumatologic or neurological diseases

Patients meeting ASAS criteria for radiographic axial spondyloarthritis and aged over 18 years will be included after informed consent. Only those receiving biologic therapy for at least the previous 4 months with stable treatment will be enrolled.

Randomization and Blinding Participants will be randomized into intervention and control groups using stratified randomization according to age, body mass index, and disease activity (ASDAS-CRP). Randomization will be performed by an independent researcher using an online randomization system, with codes safeguarded to ensure allocation concealment. The outcome assessor will be blinded to group allocation.

Interventions

Control Group (Standard Care): Patients will continue routine medical treatment and will be advised to follow general healthy eating guidelines.

Mediterranean Diet Group: Patients will follow a structured Mediterranean diet program designed with a dietitian. Dietary adherence will be reinforced through telephone follow-ups every 10 days.

Assessments will be performed at baseline and at the end of the 3-month intervention.

Primary Outcome

Change in Ankylosing Spondylitis Disease Activity Score with C-reactive protein (ASDAS-CRP).

Secondary Outcomes

Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

ASDAS using erythrocyte sedimentation rate (ASDAS-ESR)

Bath Ankylosing Spondylitis Functional Index (BASFI)

Bath Ankylosing Spondylitis Metrology Index (BASMI)

Hospital Anxiety and Depression Scale (HADS)

Quality of life (SF-36)

International Physical Activity Questionnaire (IPAQ)

Pittsburgh Sleep Quality Index (PSQI)

Functional Assessment of Chronic Illness Therapy-Fatigue (FACIT-Fatigue)

Health Assessment Questionnaire (HAQ)

Medication adherence (MMAS-8)

Mediterranean diet adherence (PREDIMED score)

Hand grip strength

Body composition analysis (InBody270 bioelectrical impedance analysis)

Power Analysis The required sample size was calculated using G*Power software with 80% power and a type I error of 0.05. A total of 55 participants per group was determined, accounting for a 10% dropout rate.

Statistical Analysis All analyses will be performed using SPSS software. The Shapiro-Wilk test will assess normality of data. Baseline characteristics will be compared using independent t-tests or Mann-Whitney U tests as appropriate. Repeated-measures ANOVA will be used for within- and between-group comparisons of primary and secondary outcomes at baseline and 3 months. Bonferroni correction will be applied for multiple comparisons. Categorical variables will be analyzed using Chi-square or Fisher's exact test. A p-value \<0.05 will be considered statistically significant.

03

Conditions studied

  • Axial Spondyloarthritis (Ankylosing Spondylitis)

Browse trials for

Keywords

  • Mediterranean Diet
  • Axial Spondyloarthritis
  • Ankylosing Spondylitis
  • Biologic Therapy
  • bDMARD
04

In context

Spondylitis, Ankylosing Reclassified

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

This study's planned enrollment of 110 is above the median of 87 across 304 interventional studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

This is the only study on the registry with Sinem Kübra Beke as lead sponsor.

Compared within Spondylitis, Ankylosing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Axial Spondyloarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years.

Diagnosis of ankylosing spondylitis according to the Assessment of SpondyloArthritis International Society (ASAS) classification criteria.

No dietary changes within the past 3 months.

Stable treatment with NSAIDs or DMARDs for at least the previous 4 months.

Receiving biologic therapy (bDMARDs) with no changes in medication for the last 4 months.

Willingness and ability to provide written

Exclusion criteria

Exclusion Criteria:

  • Pregnancy or breastfeeding.

Nutritional restrictions preventing adherence to the Mediterranean diet (e.g., severe food allergies).

Participation in another diet- or exercise-based intervention program within the last 6 months.

Presence of another rheumatologic disease or history of neurological disorders.

Individuals younger than 18 years.

to body composition analysis (e.g., cardiac pacemaker, pregnancy).

Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    Mediterranean Diet Group

    Participants will follow a structured Mediterranean diet program designed and supervised by a dietitian. Adherence will be reinforced through follow-up phone calls every 10 days. Assessments will be performed at baseline and after 3 months.

    Behavioral: Mediterranean Diet

  • Active comparator
    Control Group (Standard Care)

    Participants will continue their standard medical treatment and will receive general healthy eating advice in addition to routine care. Assessments will be performed at baseline and after 3 months

    Behavioral: Healthy Eating Advice

Interventions

  • BehavioralMediterranean Diet

    "A structured Mediterranean diet program designed and supervised by a dietitian. The program emphasizes high consumption of olive oil, vegetables, fruits, legumes, whole grains, and fish; moderate intake of dairy and poultry; and low intake of red meat and processed foods. Adherence will be monitored through 10-day interval follow-up phone calls. Assessments will be conducted at baseline and 3 months

  • BehavioralHealthy Eating Advice

    Participants will continue their standard medical treatment and will receive general healthy eating advice, as routinely recommended in clinical practice. No additional structured dietary program will be provided. Assessments will be performed at baseline and at 3 months.

07

What researchers measure

Primary outcomes

  1. ASDAS-CRP (Ankylosing Spondylitis Disease Activity Score with C-reactive protein)

    ASDAS-CRP is a validated composite index for disease activity in ankylosing spondylitis. Disease activity states are classified as inactive (\<1.3), low (\<2.1), high (\<3.5), and very high (\>3.5). The primary outcome is the change in ASDAS-CRP score from baseline to 3 months.

    Time frame: Baseline and 3 months

Secondary outcomes

  1. Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)

    BASDAI assesses fatigue, spinal pain, peripheral joint pain/swelling, localized tenderness, and morning stiffness (severity and duration) using six 10 cm visual analog scale (VAS) questions. Scores range from 0 (best) to 10 (worst).

    Time frame: Baseline and 3 months

  2. th Ankylosing Spondylitis Functional Index (BASFI)

    BASFI evaluates functional ability through 10 daily activity questions scored on a 10 cm VAS. Higher scores indicate worse function.

    Time frame: Baseline and 3 months

  3. Bath Ankylosing Spondylitis Metrology Index (BASMI)

    BASMI assesses spinal and hip mobility based on five measures: lateral lumbar flexion, tragus-to-wall distance, lumbar flexion, intermalleolar distance, and cervical rotation. Scores range from 0 (no limitation) to 10 (severe limitation).

    Time frame: Baseline and 3 months

  4. Hospital Anxiety and Depression Scale (HADS)

    4-item questionnaire (7 anxiety, 7 depression). Scores \>10 for anxiety (HADS-A) and \>7 for depression (HADS-D) indicate possible mood disorder.

    Time frame: Baseline and 3 months

  5. Quality of Life (Short Form-36, SF-36)

    SF-36 evaluates eight domains of health status (physical, role-physical, role-emotional, pain, general health, vitality, social, mental health). Scores 0-100; higher scores indicate better quality of life.

    Time frame: Baseline and 3 months

  6. Sleep Quality (Pittsburgh Sleep Quality Index, PSQI)

    Self-reported questionnaire assessing sleep quality and disturbances over 1 month. Scores ≥5 indicate poor sleep quality.

    Time frame: Baseline and 3 months

  7. Medication Adherence (Morisky Medication Adherence Scale, MMAS-8)

    8-item scale assessing adherence, categorized as low (\<6), medium (6-7), or high (8).

    Time frame: Baseline and 3 months

  8. Mediterranean Diet Adherence (PREDIMED Score)

    14-item questionnaire assessing adherence to the Mediterranean diet. Scores ≤5 = poor, 6-9 = moderate, ≥10 = good adherence.

    Time frame: Baseline and 3 months

  9. Hand Grip Strength

    Measured with a calibrated Jamar hydraulic hand dynamometer for both dominant and non-dominant hands. The mean of three measurements will be recorded in kilograms.

    Time frame: Baseline and 3 months

  10. Body Composition (InBody 270 Bioelectrical Impedance Analysis)

    Segmental skeletal muscle mass (arms, legs, trunk) will be assessed using multi-frequency bioelectrical impedance analysis (DSM-BIA).

    Time frame: Baseline and 3 months

08

Study locations

1 site
09

References and documents

Publications

  • Ometto F, Ortolan A, Farber D, Lorenzin M, Dellamaria G, Cozzi G, Favero M, Valentini R, Doria A, Ramonda R. Mediterranean diet in axial spondyloarthritis: an observational study in an Italian monocentric cohort. Arthritis Res Ther. 2021 Aug 20;23(1):219. doi: 10.1186/s13075-021-02600-0. PubMed 34416917 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — No individual participant data (IPD) will be shared due to patient privacy concerns and local data protection regulations. Only aggregate study results will be published in scientific journals and presented at conferences.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jan 2027, 15 months later.

Of 62 non-industry interventional studies with no phase under Spondylitis, Ankylosing, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's planned 15 months is above that.

Counting every sponsor, half of 65 studies reached it within 12 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 28, 2025
First posted
Sep 12, 2025
StartEst.
Sep 8, 2025
Primary completionEst.
Jan 1, 2027
CompletionEst.
Jan 1, 2027
Last update
Sep 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT07170384
Lead sponsor
Sinem Kübra Beke
Responsible party
Sinem Kübra Beke (Associate Professor, TC Erciyes University) — Sponsor-investigator
First posted
Sep 12, 2025
Start date
Sep 8, 2025 (estimated)
Primary completion
Jan 1, 2027 (estimated)
Completion
Jan 1, 2027 (estimated)
Last update
Sep 12, 2025

Study contacts

Gizem Cengiz, Associate Professor
Contact
gizemcng@outlook.com
+90 530 923 8176

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion